Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

December 18, 2017

RXi scarring treatment trial yields positive results

Brad Kane Geert Cauwenbergh, president and CEO, RXi Pharmaceuticals Corp.

RXi Pharmaceuticals, a clinical-stage drug company based in Marlborough, on Monday announced positive results from a clinical trial of its lead drug candidate, RXI-109, a compound designed to reduce hypertrophic scarring after surgery and traumatic injury.

According to a company statement, scars treated in the Phase 2 clinical trial showed statistically-significant improvement in appearance following scar revision surgery, and treatment with RXI-109, and the treatment was shown to be safe and well tolerated. In addition, cosmetic outcomes of RXI-109 treated scars were highly preferred over the untreated revised scars, by both investigators and patients, according to RXi.

According to the company, there is a high, unmet need for treatments to reduce scarring after surgery, with a market potential as high as $1.5 billion. Currently, cosmetic therapies such as Botox are used to reduce the appearance of scars, but there is no approved treatment to prevent hypertrophic scarring.

Sign up for Enews

WBJ Web Partners

Related Content

0 Comments

Order a PDF